ORLANDO—Statin use is associated with a nearly two thirds reduced risk of death from prostate cancer, a study found. The finding is based on a study of 760 New Jersey men—380 cases (men aged 55-79 who ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch ...

Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free ...

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...